Prostate cancers have been notoriously resistant to immunotherapy modalities primarily because the tumors exist in immunologically “cold” microenvironments. This immunological coldness implies a paucity of immune effector cells infiltrating the tumor, limiting the body’s ability to recognize and attack cancer cells effectively. Conventional androgen deprivation therapy (ADT), the cornerstone hormone treatment for prostate cancer, transiently reverses this resistance by recruiting immune cells into the tumor microenvironment, ostensibly “heating up” the tumor. However, this incitement is fleeting and complicated by the concurrent rise of regulatory T cells (Tregs), immunosuppressive cells that act as checkpoints disabling the immune system’s antitumor response.

Recognizing this dichotomy—the dual-edged impact of ADT—the research team pursued a novel therapeutic strategy aimed at selectively disarming the suppressive influence of Tregs, thereby unleashing a more robust and sustained immune attack. Leveraging the first-in-human randomized early-phase clinical trial design, the investigators administered an engineered Fc-enhanced anti-CTLA-4 antibody, known as BMS-986218, alongside standard ADT to evaluate the safety and immunomodulatory effects within primary tumors prior to prostatectomy.

CTLA-4, a critical immune checkpoint receptor, is highly expressed on Tregs residing within tumors, making it a strategic target for selective depletion. The Fc enhancement of BMS-986218 augments the antibody’s ability to engage the immune system’s effector mechanisms, such as antibody-dependent cellular cytotoxicity, leading to more effective elimination of Tregs within the tumor milieu. This refined targeting contrasts with earlier CTLA-4 inhibitors, which lacked this enhanced capacity and breadth of selective Treg depletion, thus limiting clinical efficacy.

The trial enrolled 24 men diagnosed with high-risk localized prostate cancer, offering a critical window to interrogate the tumor immune microenvironment using resected specimens post-treatment, rather than relying on small biopsies often limited in immune cell yields. Comprehensive immunophenotyping and advanced spatial profiling technologies revealed a pronounced decrease in intratumoral Tregs in the cohort receiving the combined therapy compared to those on hormone therapy alone. Importantly, this Treg reduction correlated with a favorable clinical outcome, as patients exhibiting the most profound Treg depletion remained cancer-free during subsequent follow-ups.

Beyond the immunological findings, the study illuminates the complex interplay within the prostate tumor microenvironment by mapping changes at the single-cell level. This granular dissection disclosed how the therapy reconfigures immune cell composition and function, enhancing effector T cell infiltration and activity while dampening immunosuppressive networks orchestrated by Tregs. Such insights provide an unprecedented blueprint for understanding the nuanced immune dynamics governing prostate cancer progression and therapeutic response.

The clinical significance of selectively targeting Tregs in early-stage prostate cancer cannot be overstated. By effectively releasing the brakes imposed on antitumor immunity, this approach synergizes with hormone therapy’s initial immunostimulatory effects, potentially preventing the insidious progression to metastatic disease—a stage marked by poorer prognosis and diminishing therapeutic options. Dr. Casey Ager, the study’s lead author and immunology researcher at Mayo Clinic, emphasizes that these are patients with localized disease who stand to benefit most, potentially achieving durable remission or cure through this combined immunotherapeutic strategy.

From an immunobiological perspective, androgen deprivation reduces circulating testosterone and other male hormones that fuel prostate cancer growth, simultaneously altering systemic and local immune landscapes. While ADT enhances infiltration of various immune effectors such as cytotoxic T lymphocytes, the concomitant recruitment of Tregs functions as a compensatory immune checkpoint, neutralizing this response and enabling cancer immune escape. The introduction of BMS-986218 deftly pivots this balance by specifically eroding the Treg compartment within tumors, thereby amplifying immune-mediated tumor clearance.

Critically, the trial underscores the feasibility and safety of integrating experimental immunotherapies in the neoadjuvant setting—before surgical excision—in patients at high risk for prostate cancer progression. This timing not only maximizes immunological impact when tumor burden is confined but also facilitates comprehensive tissue analyses post-treatment to inform biomarker development and future therapeutic refinement. The extensive dataset generated by parallel multi-omics and spatial profiling technologies will serve as a rich resource to substantiate biomarkers predictive of response and resistance, accelerating precision immunotherapy paradigms for prostate cancer.

This pioneering research carries profound implications beyond prostate cancer, illustrating a conceptual framework wherein targeted modulation of tumor-resident regulatory T cells can rejuvenate immunity in immunologically cold malignancies. Success here could catalyze similar strategies across a spectrum of solid tumors traditionally refractory to immunotherapy. Moreover, Fc engineering of antibodies to enhance Treg depletion represents a versatile platform technology promising to redefine immune checkpoint blockade efficacy.

As the immunotherapy field continues to evolve, these findings distinctly highlight that early intervention utilizing combinatorial regimens can alter the trajectory of cancer progression. By addressing the intrinsic immune suppression that characterizes prostate cancer and harnessing the synergistic potential of hormone therapy with next-generation checkpoint modulation, this study charts a compelling course toward durable remissions and improved patient outcomes.

In conclusion, this study marks a watershed moment in prostate cancer immunotherapy research, delivering the first clinical proof that selective targeting of regulatory T cells via an Fc-enhanced anti-CTLA-4 antibody substantially augments the immune milieu altered by hormone therapy. The ability to manipulate the immunosuppressive tumor microenvironment at such an early disease stage holds the promise of arresting progression before metastasis, thus improving quality of life and survival for countless patients. As these early-phase findings pave the way for larger confirmatory trials, the oncology community eagerly anticipates the broader clinical translation of this innovative neoadjuvant immunotherapeutic strategy.

Subject of Research: Prostate cancer immunotherapy, regulatory T cell targeting, androgen deprivation therapy enhancement
Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: a randomized phase I trial
News Publication Date: 26-Feb-2026
Web References: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00055-8
References: DOI 10.1016/j.xcrm.2026.102638
Keywords: Prostate cancer, Immunotherapy, Regulatory T cells, CTLA-4, Androgen deprivation therapy, Fc-enhanced antibodies

The study retrospectively analyzed clinical data from 113 prostate cancer patients treated at the UCLA Jonsson Comprehensive Cancer Center. All participants underwent PSMA PET/CT scans for recurrent disease evaluation, revealing critical insights about the anatomical extent and biological behavior of residual or metastatic lesions. PSMA PET/CT, by targeting membrane antigen expression on prostate cancer cells, provides superior sensitivity and specificity over conventional imaging, enabling early detection even at low PSA levels. This molecular imaging modality has rapidly become a vital tool for pinpointing occult disease sites post-prostatectomy and determining appropriate salvage therapy strategies.

Findings indicated that patients with no visible disease on PSMA PET/CT (classified as T0N0M0) experienced the most favorable progression-free survival. For this subgroup, whole-pelvis radiotherapy (WPRT) did not show significant benefits beyond prostate bed radiotherapy alone, suggesting that extensive radiation fields might be unnecessary when imaging reveals no overt disease. This emphasizes the potential to minimize overtreatment and associated toxicities by leveraging precise imaging.

Conversely, individuals with local, visible recurrence confined to the prostate bed (TrN0M0) demonstrated significant PFS improvement when treated with WPRT compared to prostate bed radiotherapy alone. This highlights the importance of incorporating imaging evidence of localized recurrence into radiation planning, supporting more aggressive therapy aimed at controlling subclinical micrometastases within the pelvic lymphatic drainage region. Such data underscore the principle that therapeutic volumes should be modulated based on anatomically accurate tumor burden assessment.

In cases where PSMA PET/CT revealed nodal or distant metastatic disease, the addition of androgen deprivation therapy (ADT) correlated with notably better PFS outcomes. ADT—a cornerstone systemic therapy targeting androgen receptor signaling—appears especially critical in controlling biologically aggressive and disseminated prostate cancer identified by advanced imaging. This multidimensional strategy combining imaging-guided radiotherapy with systemic hormonal therapy exemplifies personalized oncology, maximizing efficacy while potentially sparing patients from unnecessary toxicity.

John Nikitas, MD, the study’s lead investigator from UCLA, emphasized that routine utilization of PSMA PET/CT scans following biochemical recurrence provides clinicians with indispensable data that frequently alter treatment recommendations. In contrast to PSA levels alone, which were not strongly predictive of response to salvage therapies, PET/CT imaging delineates disease distribution and guides decisions that influence long-term outcomes. His remarks underscore the paradigm shift from relying solely on serum biomarkers toward integrated molecular imaging in prostate cancer care.

Beyond survival metrics, the study suggests that PSMA PET/CT can spare patients from the side effects of overly aggressive or inappropriate therapies. By objectively stratifying recurrent disease patterns—ranging from absent to localized versus metastatic—clinicians can select treatment intensities that provide optimal therapeutic gain without excessive morbidity. This precision approach enhances quality of life for men undergoing salvage therapy.

E. Christopher Dee, MD, from Memorial Sloan Kettering Cancer Center, who was not involved in the study, commented on the transformative potential of PSMA PET imaging. He pointed out that this technology enables a shift from one-size-fits-all radiation regimens to personalized treatments informed by anatomy and tumor biology. He highlighted that detecting cancer locations even at low PSA levels can fundamentally change practice patterns and improve patient outcomes. His insights further validate the clinical value of integrating functional molecular imaging into secondary and salvage prostate cancer management.

This research opens new avenues for prospective clinical trials aimed at refining the synergistic roles of imaging, radiotherapy, and systemic treatments in the salvage setting. The ability to visualize occult disease burdens non-invasively offers opportunities to test novel therapeutic combinations and dosing regimens with unprecedented precision and adaptive strategies aligned to changing tumor landscapes detected by PSMA PET/CT.

Furthermore, the adoption of PSMA PET/CT has implications beyond improved clinical outcomes. It promotes cost-effectiveness by avoiding unnecessary treatments and associated complications, thereby potentially reducing healthcare system burdens. The enhanced accuracy in staging and treatment response monitoring also contributes to more efficient resource allocation in oncology care.

Mechanistically, PSMA PET/CT imaging capitalizes on the overexpression of PSMA on prostate cancer cells and near absence in most normal tissues, generating high tumor-to-background contrast. Coupled with hybrid PET/CT technology, it allows simultaneous anatomical localization and molecular characterization, surpassing conventional imaging modalities such as bone scans or CT alone. This dual modality approach provides comprehensive insights that inform clinical decision-making with unparalleled granularity.

Overall, this study marks a significant milestone in the journey toward precision oncology for prostate cancer recurrence. It exemplifies how integrating molecular imaging with conventional treatment paradigms can tailor interventions to individual disease biology and distribution, ultimately enhancing patient outcomes and quality of life. As PSMA PET/CT becomes more widely accessible, its impact on guiding salvage radiotherapy and systemic treatment strategies is poised to expand exponentially, fostering more personalized, effective, and less toxic prostate cancer care worldwide.

Subject of Research: Prostate cancer patients with biochemical recurrence after radical prostatectomy

Article Title: Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

News Publication Date: February 9, 2026

Web References:

• Full article and commentary available at JNCCN.org
• Commentary titled “The Last Word” at JNCCN.org

Image Credits: Credit to NCCN

Keywords: Prostate cancer, PSMA PET/CT, salvage radiotherapy, biochemical recurrence, androgen deprivation therapy, progression-free survival, molecular imaging, personalized oncology, radiation therapy, prostate-specific antigen, metastatic disease, precision medicine

image: Figure 2: Maximum-intensity projection images from [⁶⁸Ga]Ga-PSMA and [¹⁸F]-FDG PET before treatment, and [¹⁷⁷Lu]Lu SPECT displayed without and with (red) segmentation with SUV of >3 in 74-y-old mCRPC patient. [¹⁷⁷Lu]Lu-PSMA therapy was stopped at third injection despite dramatic decrease in PSA because of lack of favorable impact on symptoms and worsening clinical condition, and patient died 6 months later. High TLA was observed after second and third injections with advent of new bone lesions (orange arrows), both being indicative of poor prognosis.

view more 

Credit: Image created by L Imbert and C Boursier, et al., Regional University Hospital Center in Nancy, France.

Reston, VA (October 13, 2025)–A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong prognostic information, treatments for prostate cancer patients can be personalized according to tumor evolution, significantly impacting their overall survival. This research was published online in The Journal of Nuclear Medicine.

¹⁷⁷Lu-PSMA is a highly-targeted radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC). Conventional monitoring techniques during ¹⁷⁷Lu-PSMA therapy include analysis of the clinical condition and prostate-specific antigen (PSA) measurements. PSMA PET/CT is also performed before and during treatment. ¹⁷⁷Lu SPECT imaging after each injection has shown potential for treatment monitoring, however, it often has long imaging times.

“This drawback makes it challenging to systematically perform SPECT after each ¹⁷⁷Lu-PSMA injection including after the last injection, which may provide the most substantial prognostic information,”  said Laetitia Imbert, PhD, a physicist at Regional University Hospital Center in Nancy, France. “However, this technical issue can now be largely overcome with the advent of high-sensitivity 360 cadmium zinc telluride (CZT) SPECT systems, which enable total-body SPECT recordings in under 20 minutes. Our study sought to explore this new SPECT approach further in regard to ¹⁷⁷Lu PSMA treatment monitoring.”

The retrospective study included 72 mCRPC patients who received up to six ¹⁷⁷Lu-PSMA treatments. All patients underwent ⁶⁸Ga-PSMA-11 PET before initial treatment, had their PSA measured before each injection, and underwent ¹⁷⁷Lu-PSMA CZT SPECT after each injection. Quantitative image analysis and statistical image analysis were performed to predict overall survival.

Most PSA, PET, and CZT SPECT variables were significant univariate predictors of overall survival. However, only two ¹⁷⁷Lu CZT SPECT variables were multivariate predictors: detection of new bone lesions during treatment and final total lesion activity (TLA). Means of survival times were 19.7 months in the 19 patients who showed no new bone lesions and a low level of TLA; 14.4 months in the 19 patients with only one of these two criteria; and 6.9 months in the 19 patients with neither criterion. 

“Fighting cancer is a battle against time, as the disease can evolve rapidly. This new scintigraphy camera will assist in changing treatment plans for patients who do not respond well, at the earliest stage possible, noted Caroline Boursier, MD, a physician at Regional University Hospital Center in Nancy, France. Improvements could be achieved by adjusting the injected activity of ¹⁷⁷Lu-PSMA, substituting this radionuclide therapeutic agent with an alternative, or combining it with other cancer treatments such as chemotherapy, external radiotherapy, immunotherapy, or anti-angiogenic drugs.”

She added, “Logistically, monitoring patients with CZT SPECT is easy to schedule because of the very fast imaging times and the fact that no additional tracer injection is required. Scintigraphy imaging can therefore begin as soon as the patient arrives at the nuclear medicine department, and in our experience, they can leave in less than 30 minutes.”

The authors of Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [¹⁷⁷Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360 Cadmium Zinc Telluride SPECT include Julien Kunsch, Pierre Olivier, and Marine Claudin, Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France; Timoth e Zaragori, Innovation Technologique, CIC 1433, CHRU-Nancy, INSERM, Universit de Lorraine, Nancy, France, and IADI, INSERM, U1254, Universit de Lorraine, Nancy, France; Pierre-Yves Marie, S bastien Heyer, Antoine Verger, Laetitia Imbert, and Caroline Boursier, Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France, and IADI, INSERM, U1254, Universit de Lorraine, Nancy, France; and Perrine Raymond, Department of Endocrinology, CHRU Nancy, Nancy, France.

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at 

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.

Journal

Journal of Nuclear Medicine

DOI

10.2967/jnumed.125.270358

The Steven A. Leibel Memorial Award, jointly presented by the American Society for Radiation Oncology (ASTRO) and the American Board of Radiology (ABR) Foundation, acknowledges the innovative contributions and leadership that early-career clinicians bring to radiation oncology. Dr. Kishan’s selection reflects his commitment to integrating advanced radiation techniques with translational and clinical research to improve patient outcomes substantially. This national honor not only celebrates his research accomplishments but also highlights his dedication to transforming cancer treatment by refining and individualizing radiotherapeutic strategies.

At UCLA, Dr. Kishan has established a robust clinical and translational research agenda spanning over eight years, focusing extensively on genitourinary oncology. As chief of the genitourinary oncology service, he is internationally renowned for his expertise in stereotactic body radiotherapy (SBRT) and MRI-guided radiation therapy. SBRT, known for delivering high doses of radiation with sub-millimeter precision, significantly reduces treatment time and spares adjacent healthy tissues. MRI-guided radiation therapy, meanwhile, allows for real-time visualization of tumors during treatment, enabling adaptive treatments that account for anatomical changes and tumor motion, thus enhancing therapeutic efficacy.

Dr. Kishan has significantly contributed to the design and execution of several landmark trials that push the boundaries of radiation oncology. Among these, the MIRAGE study utilized MRI-guided SBRT for prostate cancer, demonstrating superior toxicity profiles and cancer control rates compared to conventional approaches. The LUNAR trial, another key endeavor, explores precise dose escalation in bladder cancer treatments while mitigating treatment-related side effects. Additionally, the recently initiated HEATWAVE trial investigates novel thermoradiotherapy combinations to sensitize tumors while preserving healthy tissue integrity, underpinning the future direction of multimodal cancer therapies.

His scholarly output is equally impressive, with over 310 peer-reviewed publications in top-tier medical journals such as JAMA, The Lancet Oncology, and the Journal of Clinical Oncology. This extensive body of work provides the scientific community with critical evidence on enhancing the therapeutic window of radiation therapy—maximizing tumor eradication while minimizing adverse effects. Dr. Kishan’s research emphasizes the dual goals of improving cancer control rates and patient quality of life, reflecting a patient-centered approach in oncologic care.

Central to Dr. Kishan’s research philosophy is his focus on translational science, bridging the gap between laboratory discoveries and clinical application. His investigations into molecular imaging and nanotechnology facilitate the identification of radiobiological markers and enable theranostic or targeted therapeutic approaches. By harnessing molecular imaging modalities, his work aims to better characterize tumor heterogeneity, understand resistance mechanisms, and tailor radiation doses to the biological behavior of individual cancers, thus advancing personalized medicine in oncology.

Dr. Kishan’s dedication extends beyond research; he is also deeply committed to compassionate clinical care and mentorship. He has been recognized with the Leonard Tow Humanism in Medicine Award in 2021, underscoring his empathetic approach toward patients and his role in nurturing the next generation of clinicians and researchers. His mentorship fosters an environment where scientific inquiry and clinical excellence coexist, ensuring sustained innovation in cancer treatment paradigms.

The support Dr. Kishan has garnered from prestigious agencies, including the National Institutes of Health, the Department of Defense, and the Prostate Cancer Foundation, speaks to the transformative potential of his work. These grants facilitate high-impact research initiatives aimed at improving survival outcomes and reducing the morbidity associated with current cancer therapies. His ability to secure sustained funding reflects the confidence of the scientific and medical communities in the significance and rigor of his research portfolio.

In the context of prostate cancer, Dr. Kishan’s work has redefined treatment paradigms by demonstrating that advanced precision radiation techniques can rival, and potentially surpass, traditional approaches in both efficacy and safety. This work aligns with emerging trends in oncology focused on minimally invasive treatments that maintain high cure rates without compromising urinary, sexual, or bowel function. His research increasingly informs clinical guidelines, helping set new standards for care.

Bladder cancer research under Dr. Kishan’s leadership similarly benefits from innovations in radiation delivery and combination therapies. By employing hypofractionated radiation schedules coupled with systemic agents, his research aims to enhance tumor control while shortening overall treatment durations. Such advances have the potential to transform bladder cancer management, reducing healthcare costs and patient burden without compromising outcomes.

Dr. Michael Steinberg, professor and chair of radiation oncology at UCLA’s David Geffen School of Medicine and director of Clinical Affairs at the UCLA Health Jonsson Comprehensive Cancer Center, lauds Dr. Kishan’s scientific rigor and leadership. According to Dr. Steinberg, Dr. Kishan’s commitment exemplifies UCLA’s mission to drive innovation in cancer research and deliver state-of-the-art care, highlighting the institution’s role as a hub for cutting-edge oncology advancements.

In summary, the recognition of Dr. Amar Kishan with the 2025 Steven A. Leibel Memorial Award is a testament to his transformative contributions to radiation oncology. His pioneering work in precision radiation techniques, translational research, and compassionate patient care continues to advance the frontier of cancer treatment. The impact of his research promises to enhance therapeutic efficacy, reduce treatment-related morbidity, and improve the lives of countless patients facing prostate and bladder cancers worldwide.

Subject of Research: Radiation therapy advancements and translational research in prostate and bladder cancers
Article Title: Dr. Amar Kishan Honored with the 2025 Steven A. Leibel Memorial Award for Innovations in Radiation Oncology
News Publication Date: 2024
Web References:
– https://www.uclahealth.org/providers/amar-kishan
– https://www.uclahealth.org/cancer
References:
– JAMA, The Lancet Oncology, Journal of Clinical Oncology (select publications by Dr. Amar Kishan)
Image Credits: Information not provided
Keywords: Radiation therapy, Cancer, Prostate cancer, Medical treatments

Prostate cancer remains the second most prevalent malignancy among men globally, often presenting a formidable challenge when it recurs after initial treatment. Oligorecurrent prostate cancer, characterized by a small number of new metastatic lesions, demands precise and effective therapeutic interventions. SBRT, a form of high-precision radiation that targets tumors while sparing surrounding healthy tissue, has become the standard for managing these cases. However, many patients eventually experience relapse, primarily due to microscopic disease invisible on conventional imaging.

To address this, the UCLA-led LUNAR phase 2 trial investigated whether incorporating a PSMA-targeted radioligand, specifically the molecule 177Lu-PNT2002, prior to SBRT could better eradicate both visible and occult prostate cancer cells. Prostate-specific membrane antigen (PSMA) is a protein abundantly expressed on prostate cancer cells, making it an ideal target for radioligand therapies. Unlike traditional radiation, radioligand therapy delivers targeted radiation via radioactive isotopes linked to molecules that bind directly to cancer cells, minimizing collateral damage to healthy tissues.

The trial enrolled 92 men with oligorecurrent prostate cancer and randomly assigned them to two groups. The control arm received SBRT alone, while the experimental arm received two doses of 177Lu-PNT2002 before SBRT. Patients were monitored through prostate-specific antigen (PSA) blood tests and advanced PSMA PET imaging to evaluate disease progression. Remarkably, those treated with the combination therapy exhibited a median progression-free survival of 17.6 months, more than twice that of the SBRT-only group, which demonstrated 7.4 months.

This substantial improvement translated into a 63% reduction in the combined risk of cancer progression, initiation of hormone therapy, or death. Importantly, the addition of 177Lu-PNT2002 delayed the initiation of androgen deprivation therapy (ADT)—a cornerstone treatment for advanced prostate cancer known for its severe side effects such as fatigue, sexual dysfunction, and bone density loss. Men receiving the combination therapy enjoyed a median of 24.3 months before hormone therapy became necessary, compared to 14.1 months in the SBRT-alone cohort.

The success of this combined modality stems not only from its capacity to target PSMA-expressing cancer cells visible on PET scans but also from its potential to eradicate microscopic disease lingering beneath the detection threshold. By harnessing PSMA PET imaging to precisely guide SBRT targeting and coupling it with radioligand therapy, the researchers created a dual-attack strategy that addresses both macroscopic and microscopic cancer deposits.

Additionally, the LUNAR trial delved into biological markers that could predict patient responses to treatment. The researchers analyzed T cell receptor changes post-SBRT, immunological shifts associated with improved clinical outcomes. Furthermore, a gene expression signature encompassing 20 genes linked to immune function and DNA repair differentiated patients at higher risk of disease progression from those more likely to benefit from therapy, opening avenues toward personalized treatment approaches.

Despite the profound benefits observed, the trial underscored ongoing challenges, as 64% of men still experienced disease progression. This high relapse rate highlights the complexity of micrometastatic prostate cancer and suggests the need for further refinements in both therapeutic delivery and precision targeting.

Dr. Amar Kishan, the executive vice chair of radiation oncology and co-director of the cancer molecular imaging, nanotechnology, and theranostics program at UCLA, emphasized the significance of these findings: “Our research provides pivotal proof of principle that radioligand therapy can be effectively and safely integrated earlier in prostate cancer treatment, offering patients meaningful delays in disease progression and hormone therapy initiation without additional toxicity.”

Moreover, Dr. Jeremie Calais, the trial’s senior author and director of the Ahmanson Translational Theranostics Division, highlighted the synergy achieved through collaboration between radiation oncology and nuclear medicine. This interdisciplinary approach exemplifies the promise of theranostics—a field combining diagnostic imaging and targeted therapy—to revolutionize cancer care paradigms.

The safety profile of the combination therapy was also encouraging, with minimal adverse effects reported, reinforcing its potential for broader clinical application. Nevertheless, the investigators acknowledge the necessity for longer-term follow-up and exploration of strategies to enhance response rates, such as optimizing dosing schedules or combining with immunotherapies.

This study not only propels forward the clinical utility of PSMA-targeted radioligand agents beyond advanced metastatic settings but also redefines the therapeutic landscape for men with oligorecurrent disease. By extending progression-free survival and postponing hormone therapy, this approach promises to improve both survival and quality of life for countless patients worldwide.

Funded by Lantheus, the LUNAR trial represents a milestone in prostate cancer research, illuminating a new path for early intervention that leverages molecular targeting and state-of-the-art imaging to outmaneuver one of the most common and insidious cancers affecting men today.

Subject of Research: Prostate cancer treatment using PSMA-targeted radioligand therapy combined with stereotactic body radiotherapy (SBRT).

Article Title: New Radioligand Therapy Combined with Radiotherapy Doubles Progression-Free Survival in Recurrent Prostate Cancer

News Publication Date: 2025

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• 2025 ASTRO Annual Meeting Session: https://amportal.astro.org/sessions/ct-01-21645/177-lutetium-psma-neoadjuvant-to-ablative-radiotherapy-for-oligorecurrent-prostate-cancer-pri-109077
• Dr. Amar Kishan Profile: https://www.uclahealth.org/providers/amar-kishan
• Dr. Jeremie Calais Profile: https://www.uclahealth.org/cancer/members/jeremie-calais

Keywords: Prostate cancer, PSMA-targeted radioligand therapy, stereotactic body radiotherapy, oligorecurrent disease, progression-free survival, androgen deprivation therapy, theranostics, prostate-specific membrane antigen, 177Lu-PNT2002, molecular imaging, cancer treatment innovations.

At the forefront of this research is Dr. Amar Kishan, UCLA’s executive vice chair of radiation oncology and co-director of the Cancer Molecular Imaging, Nanotechnology and Theranostics Program. Dr. Kishan will unveil pivotal results from the LUNAR clinical trial, which investigates the utility of 177Lutetium-PSMA, a radioligand therapy that specifically targets prostate-specific membrane antigen (PSMA) on prostate cancer cells. Administered preemptively before ablative radiotherapy, this therapy aims to eradicate oligorecurrent prostate cancer with enhanced specificity, potentially improving outcomes by delivering cytotoxic radiation directly to malignant cells while sparing healthy tissue. The trial’s findings are slated to be a highlight of ASTRO’s scientific discourse.

In parallel, the SCIMITAR phase II clinical trial’s four-year follow-up results will be presented by Dr. Jesus Juarez Casillas, co-chief resident at UCLA’s radiation oncology department. SCIMITAR evaluates stereotactic body radiation therapy (SBRT) administered post-prostatectomy to men at elevated risk for recurrence. The trial demonstrates sustained biochemical control, with 62% of participants remaining free from cancer recurrence after four years, a promising figure that rivals traditional fractionated radiotherapy regimens. These results are significant, exemplifying SBRT’s potential to deliver high-dose radiation with millimeter precision over fewer sessions, thereby improving patient convenience and reducing healthcare burden.

UCLA’s innovations further extend into the realm of imaging, where Dr. Daniel Low showcases pioneering work on 5DCT, an advanced imaging modality designed to capture lung tumor motion with exceptional fidelity in patients exhibiting irregular respiratory patterns. Unlike conventional four-dimensional CT (4DCT), which models tumor movement along spatial dimensions synchronized with breathing phases, 5DCT incorporates additional parameters—breath rate and depth—accounting for intra- and inter-breath variability. This enhanced modeling yields artifact-free, high-resolution tumor delineations, essential for precision radiotherapy planning that mitigates radiation exposure to surrounding healthy lung tissues.

MRI-guided radiotherapy also garners significant attention, with Dr. Travis Courtney presenting comparative analyses of MRI-guided stereotactic body radiotherapy (MRgSBRT) approaches for prostate cancer. His research contrasts standard high-dose MRgSBRT against an adaptive dose-painting strategy that delivers escalated radiation doses to dominant intraprostatic lesions while attenuating exposure to adjacent normal tissues. Preliminary results reveal elevated acute toxicities—namely urinary and gastrointestinal side effects—in the dose-painted cohort as assessed by clinicians, yet patient-reported quality of life remains comparable between methods. These findings underscore the delicate balance between intensifying tumoricidal action and preserving tissue integrity, warranting further investigation into optimizing dose distribution strategies.

Complementing this, Dr. Jonathan Massachi’s work on sexual function post-MRgSBRT in the MIRAGE trial sheds light on long-term physiological ramifications. Despite the superior soft tissue contrast afforded by MRI guidance facilitating nerve and vascular sparing, approximately one-third of men in both MRI- and CT-guided arms experienced marked declines in sexual function two years post-treatment. The data suggest that even sophisticated imaging cannot fully mitigate radiation-induced neurovascular damage, highlighting an urgent need for adjunct vessel-sparing techniques or systemic protective strategies in prostate cancer radiotherapy.

Beyond prostate cancer, Dr. Miriam Lane investigates postoperative SBRT for head and neck cancers, a domain traditionally managed by protracted radiotherapy courses. Her findings reveal that SBRT, when employed as a postoperative modality for newly diagnosed or recurrent tumors, offers a well-tolerated, condensed treatment course with minimal severe acute toxicities. However, roughly half of patients experienced local recurrence within two years, emphasizing the necessity for refined patient selection and combination therapies to improve durability of response. This research paves the way for integrating SBRT into multimodal head and neck cancer management paradigms.

On the molecular front, a study led by Dr. Beth Neilsen delves into the genetic landscape of radiation-resistant prostate cancers. Utilizing genomic and transcriptomic profiling, the investigation identified an enrichment of mutations in DNA repair genes such as BRCA1, BRCA2, RAD51B, and POLQ within locally recurrent tumors post-radiotherapy. These alterations correlate with aggressive disease features, elevated genomic risk scores, and diminished androgen receptor signaling, collectively elucidating mechanisms underpinning radioresistance. Such insights provide invaluable biomarkers for risk stratification and potential targets for radiosensitizing therapies, steering toward personalized radiation oncology.

Concurrently, the integration of digital innovation into cancer education is being championed by Dr. Trudy Wu, who will moderate a session dedicated to patient empowerment through technology. This panel will explore how narrated animations, interactive videos, and tailored digital resources can demystify complex oncologic information, reduce psychological distress, and enhance shared decision-making. By harnessing these tools, clinicians aspire to foster a more informed and engaged patient population, thereby improving adherence to treatment regimens and overall outcomes.

Collectively, these multifaceted advancements showcased by UCLA researchers epitomize a paradigm shift in radiation oncology, blending molecular science, imaging innovation, clinical trial rigor, and patient-centered education. This integrated approach not only augurs improved tumor control and reduced toxicities but also reinforces the holistic care imperative in contemporary oncology practice. The ASTRO 2025 meeting will undoubtedly serve as a crucible for disseminating these transformative findings, propelling the field toward new frontiers of precision and compassion.

Dr. Michael Steinberg, chair of radiation oncology at UCLA’s David Geffen School of Medicine and director of clinical affairs at the Jonsson Comprehensive Cancer Center, eloquently summarizes this momentum: “These UCLA-led studies embody the convergence of cutting-edge technology and collaborative expertise, charting a course toward safer, more precise, and more effective cancer therapies. Our commitment to innovation continues to energize efforts to overcome cancer’s myriad challenges and enhance patient lives.”

As these presentations unfold in late September, the oncology community and patients alike watch eagerly, anticipating the ripple effects these breakthroughs will inspire in radiation therapy protocols worldwide. UCLA’s leadership in this arena reaffirms its role as a beacon of cancer research excellence, transforming scientific discovery into tangible clinical benefit.

Subject of Research: Innovations in radiation therapy for prostate, lung, and head and neck cancers, including targeted radioactive treatments, advanced imaging techniques, and patient education.

Article Title: UCLA Researchers Unveil Cutting-Edge Radiation Oncology Breakthroughs at ASTRO 2025

News Publication Date: Late September 2025 (coinciding with ASTRO Annual Meeting)

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• ASTRO Annual Meeting Abstracts Portal: https://amportal.astro.org/sessions/

Keywords: Radiation therapy, Prostate cancer, SBRT, 177Lutetium-PSMA, 5DCT imaging, MRI-guided radiotherapy, Radiosensitivity, Head and neck cancer, Cancer education, Precision oncology

Prostate cancer stands as the most frequently diagnosed cancer among men across 112 nations, with projections indicating the prevalence may double by the year 2040. The introduction of national prostate cancer screening initiatives, particularly those predicated on measuring levels of prostate-specific antigen (PSA) in the bloodstream, offers the tantalizing promise of facilitating earlier therapeutic interventions. Early detection can vastly enhance the likelihood of successful treatment and effectively circumscribe the extensive costs associated with managing advanced prostate cancer cases.

Through long-term follow-up data from ERSPC, it has been consistently affirmed that participation in PSA screening programs could correlate with a 20% reduction in the risk of dying from prostate cancer. This is an encouraging statistic that underscores the urgent need for increased participation rates, particularly among demographics traditionally less engaged with health services. The recent sub-analysis of 20 years of data during the ERSPC is pioneering in its examination of the relationship between the consistent rejection of screening invitations and an individual’s risk of mortality due to prostate cancer.

Explorations led by researchers from the Department of Urology at the Erasmus MC Cancer Institute in Rotterdam have revealed that out of a staggering 72,460 men who were invited for screening, approximately one in six—over 12,400 men—chose to skip all scheduled appointments. Alarmingly, this cohort faced a 45% elevated risk of succumbing to prostate cancer compared to their counterparts who participated in the screening process. This stark finding illuminates the potential consequences inherent in the decision to forgo screening, invoking concern about the long-term implications for public health initiatives aimed at combating prostate cancer.

When the outcomes of this group were juxtaposed with a control group—men who were never invited for screening—it was discovered that men who adhered to screening appointments enjoyed a 23% lower risk of death from prostate cancer. Conversely, the non-attendees encountered a 39% greater risk of mortality from this disease. These results emphasize the critical nature of attendance and engagement in screening programs as a determinant of health outcomes among men.

The reluctance to participate in screening appointments may stem from a convoluted array of motivators, ranging from personal beliefs to socio-cultural influences, according to Dr. Renée Leenen, the study’s lead author and a PhD researcher associated with Professor Monique Roobol’s group at the Erasmus MC Cancer Institute. Dr. Leenen articulates a pressing concern that many of those who decline screening are likely care avoiders, reflecting a broader trend of disengagement with not only personal health but also preventive healthcare practices overall.

This research propels forward the understanding that men invited to participate in screening who nevertheless choose to abstain are markedly at an enhanced risk of falling victim to prostate cancer. This information necessitates a pivot in focus in public health strategies aimed at prostate cancer prevention. An imperative persists to delve deeper into the profiles of these men, unraveling the underlying motivations for their lack of participation, and subsequently devising strategies to motivate and empower them towards screening.

Given the findings from the EAU-led PRAISE-U project, multiple EU nations are collectively striving to refine their approaches towards patient-centered, risk-based prostate cancer screening programs. Insights gleaned from this latest analysis underline the paramount importance of improving attendance rates, which are essential for ensuring the efficacy of national prostate cancer screening programs. Notably, addressing disparities in access and awareness is crucial for tapping into the potential of these high-risk groups of men.

Dr. Tobias Nordström, a Clinical Urologist at the Karolinska Institute in Sweden and a member of the EAU Scientific Congress Office, articulates that this new analysis reaffirms the overall advantages of prostate cancer screening are even more pronounced than previously understood. As national prostate screening programs are formulated, the stark implications of non-attendance among certain demographic groups necessitate targeted public health responses. This can be pivotal in altering the trajectory for men identified as being at risk of developing advanced prostate cancer, altering the landscape of treatment and outcomes significantly.

The sub-analysis incorporates a sweeping 20-year follow-up of data collected from 161,000 men aged between 55-69 years within the ERSPC across diverse European nations including Finland, the Netherlands, Italy, Sweden, Switzerland, Belgium, and Spain. The ERSPC, which launched in 1990, has systematically contributed to an evolving understanding of prostate cancer, with full results of this sub-analysis anticipated to be published later this year. As health professionals and researchers work collaboratively to unpack these findings, the implications for screening practices and the potential to enhance outcomes for men at risk remain paramount.

Overall, this research signifies a vital step in illuminating the nuanced relationship between screening participation and prostate cancer mortality risk. As awareness increases, so too does the potential for developing targeted interventions that maximize participation rates. By engaging high-risk groups and effectively addressing barriers to screening attendance, we can foster a more proactive healthcare environment that champions early detection and treatment, thereby reducing the unnecessary mortality burden of prostate cancer in men.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords: Prostate cancer, Cancer screening, Cancer risk, Cancer research, Europe, Urology, Clinical trials

Rather than viewing a prostate cancer diagnosis as a life sentence, Montgomery reassures patients that such a diagnosis is not synonymous with imminent death. The oncologist emphasizes that understanding one’s diagnosis is the first step towards effective management. Many patients may find solace in knowing that not all forms of prostate cancer necessitate immediate intervention. With the advent of active surveillance—a method where patients are monitored over time instead of starting treatment immediately—there has been a significant shift in the management of low-risk prostate cancer cases. Waiting and closely observing the disease progression can often yield excellent outcomes, alleviating the anxiety tied to traditional treatment protocols.

Recent studies reinforce Montgomery’s viewpoint on the efficacy of active surveillance. A comprehensive study released in 2024, coauthored by Dr. Daniel Lin, a urologist at UW Medicine, asserts that the 10-year mortality rate due to prostate cancer among men who opted for active surveillance was as low as 0.1%. Such statistics instill hope, indicating that many prostate cancer patients can live without aggressive treatment while still maintaining a favorable prognosis. This innovative approach challenges the old paradigms that mandated immediate intervention upon diagnosis, providing a more nuanced understanding of the disease’s variability and differentiation.

Montgomery emphasizes that prostate cancer is not a monolithic condition; it encompasses a spectrum of presentations, which necessitates a personalized approach when addressing the disease. For instance, a 50-year-old man with localized prostate cancer may warrant more aggressive treatment due to the potential longevity of his life, whereas an 80-year-old patient with a slow-growing form of the disease may consider forgoing treatment altogether. Such considerations speak to the importance of individualized patient care that prioritizes understanding the patient’s unique circumstances alongside the cancer’s biological behavior.

The implications of untreated prostate cancer particularly in older men are profound. Montgomery recounts experiences with elderly patients who, upon learning about the side effects of therapy—such as radiation—opted for a conservative approach, deciding against aggressive interventions. The insight gathered from these discussions forms the cornerstone of patient-centered care, guiding physicians to respect patient choices while ensuring they are informed about the potential repercussions of their decisions.

Moreover, Montgomery notes that advancements in treatment modalities have significantly transformed the outlook for men diagnosed at more advanced stages of prostate cancer. Metastatic prostate cancer, which occurs when cancer cells spread beyond the prostate gland, previously heralded dire prognoses. However, with the increasing arsenal of therapeutic options developed over the past two decades, the survival rates for these patients have markedly improved. The intersection of timely intervention and innovative treatments places an emphasis on a well-rounded, evidence-based approach in managing advanced prostate cancer.

It bears mentioning that the world of prostate cancer research is rapidly evolving. Recent advancements aim not only to improve survival but also to enhance the quality of life for patients undergoing treatment. Understanding who requires treatment, what type of therapy is most effective, and the timing of such interventions is becoming increasingly complex yet critical. Physicians need to navigate this intricate landscape guided by the latest research and clinical protocols while remaining attuned to the individual preferences and clinical situations of their patients.

Statistics indicate that approximately 1.5 million new prostate cancer cases arise worldwide each year, with about 75% of these cases being initially detected while still localized to the prostate. Early detection is pivotal, as it correlates with a remarkable five-year survival rate nearing 100%. This underpins the necessity for heightened awareness and proactive screening, both for potential candidates and current healthcare providers. As Montgomery advocates, conversations surrounding prostate cancer screening should be an integral part of routine healthcare discussions, particularly for men who may be at increased risk due to age or family history.

The nature of prostate cancer is often overwhelmingly influenced by genetic factors, with over 50% of the risk attributable to hereditary elements and age. This information stresses the importance of family history in assessing individual risk profiles. Genetic counseling and testing may play critical roles in providing insights that can influence screening protocols and identify early-stage diseases that demand prompt attention. Empowering individuals with knowledge about their risk factors may lead them to seek appropriate screenings and potentially improve mortality outcomes.

Prostate cancer became a focal point in public discourse following high-profile testimonies, such as that of renowned travel writer Rick Steves. His open discussion of his prostate cancer journey—from diagnosis to treatment—serves to illuminate the personal ramifications of the disease. Steves has publicly shared his successful treatment experience, including his radiation and surgical procedures undertaken at UW Medicine—providing a beacon of hope for others navigating similar roads. His triumph over cancer underscores the importance of open dialogue surrounding the disease, fostering community support and engagement for those affected.

In sum, the current landscape of prostate cancer presents patients and healthcare providers with a myriad of complexities, from understanding individual risk factors to exploring innovative treatment modalities. No longer does a prostate cancer diagnosis mean an unequivocal loss; instead, it offers a spectrum of management strategies waiting to be tailored to the individual. The evolution in the understanding and treatment of prostate cancer emphasizes an urgent call for continued research, focused patient education, and an unwavering commitment to personalized care. The future holds promise not just in survival rates but also in addressing the quality of life for men facing this health challenge.

—
Subject of Research: People
Article Title: Prostate Cancer – A Review
News Publication Date: 10-Mar-2025
Web References: http://dx.doi.org/10.1001/jama.2025.0228
References: JAMA
Image Credits: N/A

Keywords: Prostate cancer, survival rates, active surveillance, oncology, treatment options, personalized medicine, genetic factors, public health.

Published in the esteemed journal Cancer Discovery, this research stands out for its comprehensive evaluation of both hereditary genetic components and acquired mutations. By addressing these two variables, the study aims to enhance the way physicians approach the prediction and treatment of prostate cancer, particularly the more aggressive variants that necessitate urgent medical intervention. The implications of these findings could revolutionize current clinical practices, leading to personalized treatment plans based on an individual’s genetic makeup.

Dr. Paul Boutros, a prominent figure in this research and a professor at the David Geffen School of Medicine at UCLA, emphasizes the significance of understanding how inherited genetic traits interact with the timing of mutations in tumors’ DNA. This multifaceted approach offers a clearer picture of the evolutionary pathways that characterize prostate cancer. The study has confirmed a common evolutionary trajectory whereby different tumor types branch off based on early genetic alterations and the inherited genetic background of the individual, suggesting a more intricate relationship between genetic factors and tumor aggressiveness than previously understood.

Prostate cancer presents unique obstacles for researchers, mainly due to its intricate biological nature. It holds the title as one of the most common cancers worldwide, yet paradoxically, it is characterized by a relatively low mutation rate and a tendency to grow slowly, complicating diagnosis and treatment options. Current strategies primarily focus on targeting androgen receptors, leaving clinicians with limited alternatives when tumors develop resistance. This complexity has traditionally made it challenging to distinguish between aggressive tumors that require immediate intervention versus indolent forms that may never advance to a life-threatening stage.

In a concerted effort to fill the existing knowledge gaps surrounding prostate cancer genetics, the research team undertook an extensive genomic analysis of 666 localized prostate tumors. This effort represents the largest whole genome sequencing dataset of its kind, encompassing a wide spectrum of tumors, from less aggressive to highly malignant cases. The sheer volume of data analysis, over a petabyte in total, highlights the monumental effort required to unravel the intricate genetic signatures associated with differing tumor behaviors.

Utilizing cutting-edge machine learning and statistical techniques, the researchers identified 223 genomic regions frequently mutated in prostate tumors. These mutations are instrumental in the progression and dissemination of cancer, many of which conventional sequencing methods fail to detect. This innovative approach not only unveils new genetic targets for research but also illuminates the potential role of inherited genetic variations—specifically germline single nucleotide polymorphisms (SNPs)—in shaping the somatic mutations acquired over the course of tumor development.

Additionally, the research delineates how high-grade (aggressive) and low-grade (slow-growing) prostate cancers represent not fundamentally distinct diseases, but rather different stages along a continuum of tumor evolution. Both types originate from similar early-stage cellular abnormalities and share a plethora of mutations. However, aggressive cancers exhibit a propensity to acquire critical harmful mutations such as those in the BRCA2 and MYC genes earlier in their developmental narrative, thereby guiding them towards a more aggressive clinical course. The timing of these mutations appears essential, influencing the likelihood of early cancer relapse and metastasis.

Takafumi Yamaguchi, a senior bioinformatician and doctoral candidate at UCLA, underscored a crucial revelation of the study: certain germline variants significantly impact the probability of acquiring somatic driver mutations later in life. The temporal aspect of mutation acquisition plays a decisive role in determining the aggressiveness of prostate cancers. Mutations that occur during the early stages of tumor formation can drastically alter the trajectory of the cancer, often leading to pronounced clinical outcomes.

These findings not only advance the basic understanding of prostate cancer genetics but also open avenues for clinical application. The study advocates for the inclusion of diverse, multi-ancestry cohorts in future cancer research, as genetic background can play a pivotal role in shaping tumor behavior and responses to therapy. Such an inclusive approach may yield more nuanced insights into the risk factors associated with prostate cancer across different populations, ultimately enhancing the effectiveness of diagnostic and therapeutic strategies.

Dr. Boutros notes that this research paves the way for a paradigm shift in risk assessment frameworks for prostate cancer. By synergizing inherited genetic markers with advanced tumor sequencing techniques, a more accurate prognostication model could be established. This could potentially identify individuals at heightened risk for aggressive disease, offering opportunities for early intervention and tailored preventative strategies that could mitigate the development of prostate cancer.

As the next phase of this research initiative unfolds, the focus will broaden to encompass multi-ancestry populations. Such an expansion is vital, as it aims to refine risk evaluations and therapeutic approaches for prostate cancer—ultimately benefiting diverse groups of patients and enhancing overall outcomes in cancer care.

In summary, this innovative research underscores the intricate relationship between genetic factors and tumor evolution in prostate cancer, providing hope for future advancements in personalized medicine and targeted therapies. The complexity of this disease necessitates continued investigation, and the insights gleaned from this study will undoubtedly influence the trajectory of prostate cancer research for years to come.

Subject of Research: Genetic Clues to Prostate Cancer Aggressiveness
Article Title: Unraveling the Genetic Roots of Prostate Cancer Development
News Publication Date: October 2023
Web References: https://doi.org/10.1158/2159-8290.CD-23-0882
References: Full list available in the study.
Image Credits: Not specified.

Keywords: Prostate cancer, genetics, somatic mutations, germline SNPs, tumor evolution, cancer research, precision medicine, prostate tumors, cancer treatment, genetic variation, machine learning, genome sequencing.